GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Vision Biotechnology Co Ltd (ROCO:3218) » Definitions » Financial Strength

Universal Vision Biotechnology Co (ROCO:3218) Financial Strength : 7 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Universal Vision Biotechnology Co Financial Strength?

Universal Vision Biotechnology Co has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Universal Vision Biotechnology Co's Interest Coverage for the quarter that ended in Dec. 2024 was 52.17. Universal Vision Biotechnology Co's debt to revenue ratio for the quarter that ended in Dec. 2024 was 0.25. As of today, Universal Vision Biotechnology Co's Altman Z-Score is 6.91.


Competitive Comparison of Universal Vision Biotechnology Co's Financial Strength

For the Medical Devices subindustry, Universal Vision Biotechnology Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Vision Biotechnology Co's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Universal Vision Biotechnology Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Universal Vision Biotechnology Co's Financial Strength falls into.


;
;

Universal Vision Biotechnology Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Universal Vision Biotechnology Co's Interest Expense for the months ended in Dec. 2024 was NT$-7 Mil. Its Operating Income for the months ended in Dec. 2024 was NT$370 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$784 Mil.

Universal Vision Biotechnology Co's Interest Coverage for the quarter that ended in Dec. 2024 is

Interest Coverage=-1*Operating Income (Q: Dec. 2024 )/Interest Expense (Q: Dec. 2024 )
=-1*370.071/-7.093
=52.17

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Universal Vision Biotechnology Co's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(270.411 + 783.828) / 4152.46
=0.25

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Universal Vision Biotechnology Co has a Z-score of 6.91, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 6.91 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Vision Biotechnology Co  (ROCO:3218) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Universal Vision Biotechnology Co has the Financial Strength Rank of 7.


Universal Vision Biotechnology Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Universal Vision Biotechnology Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Vision Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3-1, Yuanyuan Street, 4th Floor, Nangang District, Taipei, TWN, 115
Universal Vision Biotechnology Co Ltd is mainly engaged in operating the business of (1) sales of optical devices, glasses, lens and other vision aid products (2) optometric services (3) sales and leasing of medical devices (4) providing of hospital management and technical consultancy services.

Universal Vision Biotechnology Co Headlines

No Headlines